LYEL Lyell Immunopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LYEL

Price (delayed)

$2.23

Market cap

$566.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$477.6M

Highlights
Lyell Immunopharma's debt has decreased by 10% YoY and by 2.9% QoQ
The gross profit has plunged by 100% YoY and by 100% from the previous quarter
The revenue has dropped by 100% year-on-year and by 100% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of LYEL
Market
Shares outstanding
254.1M
Market cap
$566.63M
Enterprise value
$477.6M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.86
Price to sales (P/S)
4,305.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,673.83
Earnings
Revenue
$130,000
EBIT
-$234.63M
EBITDA
-$214.38M
Free cash flow
-$166.38M
Per share
EPS
-$0.93
Free cash flow per share
-$0.66
Book value per share
$2.6
Revenue per share
$0
TBVPS
$2.99
Balance sheet
Total assets
$750.03M
Total liabilities
$95.08M
Debt
$56.89M
Equity
$654.95M
Working capital
$520.17M
Liquidity
Debt to equity
0.09
Current ratio
16.07
Quick ratio
15.83
Net debt/EBITDA
0.42
Margins
EBITDA margin
-164,909.2%
Gross margin
100%
Net margin
-180,486.2%
Operating margin
-190,006.2%
Efficiency
Return on assets
-28.8%
Return on equity
-32.7%
Return on invested capital
-36.1%
Return on capital employed
-32.8%
Return on sales
-180,486.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LYEL stock price

How has the Lyell Immunopharma stock price performed over time
Intraday
-4.29%
1 week
-25.91%
1 month
12.06%
1 year
-8.98%
YTD
14.95%
QTD
0%

Financial performance

How have Lyell Immunopharma's revenue and profit performed over time
Revenue
$130,000
Gross profit
$130,000
Operating income
-$247.01M
Net income
-$234.63M
Gross margin
100%
Net margin
-180,486.2%
The gross profit has plunged by 100% YoY and by 100% from the previous quarter
The revenue has dropped by 100% year-on-year and by 100% since the previous quarter
The operating income has declined by 32% year-on-year and by 22% since the previous quarter
The net income has declined by 28% year-on-year and by 23% since the previous quarter

Growth

What is Lyell Immunopharma's growth rate over time

Valuation

What is Lyell Immunopharma stock price valuation
P/E
N/A
P/B
0.86
P/S
4,305.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,673.83
The EPS has declined by 26% year-on-year and by 22% since the previous quarter
Lyell Immunopharma's equity has decreased by 21% YoY and by 6% from the previous quarter
The stock's P/B is 8% more than its last 4 quarters average of 0.8
The revenue has dropped by 100% year-on-year and by 100% since the previous quarter

Efficiency

How efficient is Lyell Immunopharma business performance
Lyell Immunopharma's ROIC has plunged by 69% YoY and by 33% from the previous quarter
The ROA has dropped by 57% year-on-year and by 30% since the previous quarter
The ROE has plunged by 52% YoY and by 31% from the previous quarter

Dividends

What is LYEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LYEL.

Financial health

How did Lyell Immunopharma financials performed over time
The total assets has declined by 20% year-on-year and by 6% since the previous quarter
The current ratio has declined by 9% year-on-year and by 4% since the previous quarter
Lyell Immunopharma's debt is 91% lower than its equity
Lyell Immunopharma's equity has decreased by 21% YoY and by 6% from the previous quarter
The debt to equity is up by 13% since the previous quarter and by 13% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.